Robert W. Baird Raises Twist Bioscience (NASDAQ:TWST) Price Target to $40.00

Twist Bioscience (NASDAQ:TWST) had its price target lifted by analysts at Robert W. Baird from $39.00 to $40.00 in a report issued on Friday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Robert W. Baird’s price target points to a potential downside of 2.94% from the company’s previous close.

Several other equities analysts have also issued reports on the company. The Goldman Sachs Group raised Twist Bioscience from a “neutral” rating to a “buy” rating and increased their target price for the stock from $25.00 to $45.00 in a research note on Wednesday, January 17th. Scotiabank increased their price target on Twist Bioscience from $30.00 to $43.00 and gave the company a “sector outperform” rating in a research report on Monday, February 5th. Finally, Barclays reduced their price target on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 10th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $41.67.

Twist Bioscience Price Performance

TWST opened at $41.21 on Friday. The stock’s 50-day moving average price is $34.03 and its 200 day moving average price is $31.04. Twist Bioscience has a 12-month low of $11.81 and a 12-month high of $43.21.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Thursday, May 2nd. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.05. Twist Bioscience had a negative return on equity of 30.81% and a negative net margin of 69.24%. The firm had revenue of $75.30 million for the quarter, compared to analyst estimates of $70.70 million. During the same quarter in the prior year, the company earned ($1.06) EPS. Twist Bioscience’s revenue was up 25.1% on a year-over-year basis. Analysts expect that Twist Bioscience will post -3.17 earnings per share for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, Director Robert Chess sold 4,110 shares of the stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $34.98, for a total value of $143,767.80. Following the sale, the director now owns 64,169 shares of the company’s stock, valued at approximately $2,244,631.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, COO Patrick John Finn sold 2,174 shares of the firm’s stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of $30.12, for a total transaction of $65,480.88. Following the sale, the chief operating officer now owns 176,206 shares of the company’s stock, valued at approximately $5,307,324.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Robert Chess sold 4,110 shares of the firm’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $34.98, for a total value of $143,767.80. Following the sale, the director now directly owns 64,169 shares in the company, valued at approximately $2,244,631.62. The disclosure for this sale can be found here. Insiders have sold 13,211 shares of company stock valued at $449,573 in the last quarter. Corporate insiders own 3.92% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

Several hedge funds and other institutional investors have recently made changes to their positions in TWST. Artisan Partners Limited Partnership raised its position in shares of Twist Bioscience by 111.3% during the 4th quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock worth $137,241,000 after acquiring an additional 1,961,621 shares in the last quarter. Invesco Ltd. grew its stake in Twist Bioscience by 1,496.2% during the 3rd quarter. Invesco Ltd. now owns 831,006 shares of the company’s stock worth $16,836,000 after buying an additional 778,944 shares during the last quarter. ARK Investment Management LLC grew its stake in Twist Bioscience by 6.3% during the 4th quarter. ARK Investment Management LLC now owns 7,213,257 shares of the company’s stock worth $265,881,000 after buying an additional 427,274 shares during the last quarter. AEGON ASSET MANAGEMENT UK Plc purchased a new position in Twist Bioscience during the 4th quarter worth approximately $11,956,000. Finally, Norges Bank purchased a new position in Twist Bioscience during the 4th quarter worth approximately $10,766,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.